All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fox Chase Cancer Center Researchers Show Alternate Response Criteria May Allow Early Outcome Prediction in Pancreatic Neuroendocrine Tumors

June 28th 2023

Researchers at Fox Chase Cancer Center have utilized banked computed tomography to evaluate alternate response criteria for early prediction of outcomes in rare pancreatic neuroendocrine tumors.

Galinpepimut-S Plus Nivolumab Provides Survival Benefits With Acceptable Safety in Mesothelioma

June 28th 2023

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.

FDA Grants Orphan Drug Designation to VCN-01 for Pancreatic Cancer

June 28th 2023

The FDA has granted an orphan drug designation to VCN-01, a systemic, selective, stroma-degrading oncolytic adenovirus for the treatment of patients with pancreatic cancer.

FDA Awards Orphan Drug Designation to KT-253 in AML

June 28th 2023

The FDA has granted an orphan drug designation to the novel, highly potent, and selective MDM2 degrader KT-253 for the treatment of patients with acute myeloid leukemia.

Current Treatment Perspectives for CAR T-Cell Therapy in R/R B-Cell Lymphoma

June 28th 2023

Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.

Epcoritamab Elicits an ORR of 82% in Relapsed/Refractory Follicular Lymphoma

June 28th 2023

Epcoritamab elicited a confirmed overall response rate of 82% by independent review committee assessment in patients with relapsed or refractory follicular lymphoma who received 2 or more prior systemic treatments, which exceeded the prespecified threshold for efficacy in the phase 1/2 EPCORE NHL-1 trial.

Novel CD19xCD3 Bispecific Antibody May Expand Second-Line Options in Follicular Lymphoma

June 28th 2023

Ryan Jacobs, MD, expands on the initial efficacy and safety data seen with TNB-486, the need for more data on treatment-related CRS to improve toxicity management, and next steps planned for the investigation of this and other bispecific antibodies in relapsed/refractory follicular lymphoma.

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27th 2023

Fixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lymphoma, according to updated data from the phase 2 GO29781 trial.

Quizartinib Plus Chemotherapy Improves EFS, RFS in Newly Diagnosed FLT3-ITD–Negative AML

June 27th 2023

Pau Montesinos, MD, PhD, discusses the preliminary results of the QUIWI trial, expands on the potential implications for the use of quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD–negative acute myeloid leukemia, and details the next steps for this study and future research.

Long-Term ROSEWOOD Data Confirm Efficacy of Zanubrutinib Plus Obinutuzumab in R/R Follicular Lymphoma

June 27th 2023

The addition of zanubrutinib to obinutuzumab produced superior clinical activity, prolonged survival, and had a favorable toxicity profile compared with obinutuzumab alone in heavily pretreated patients with relapsed/refractory follicular lymphoma.

NKX101 Demonstrates Early Activity in Relapsed/Refractory AML

June 27th 2023

Treatment with NKX101 led to a best composite complete response rate of 67% in patients with relapsed/refractory acute myeloid leukemia, according to updated data from a dose-expansion cohort of an ongoing phase 1 trial.

New Data Inform Treatment of Blood Cancer During Pregnancy

June 27th 2023

For the first time, researchers sought to analyze the outcomes of pregnant women with r/r lymphoma based on the timing of the pregnancy and type of lymphoma.

First-line Mitazalimab Plus Chemo Continues to Generate Responses in Metastatic PDAC

June 27th 2023

Frontline treatment with the combination of the CD40-directed monoclonal antibody agonist mitazalimab and modified FOLFIRINOX continued to produce responses in patients with metastatic pancreatic ductal adenocarcinoma.

Examining the Role of BTK Inhibitors in Mantle Cell Lymphoma

June 27th 2023

As part of the diagnostic work-up for a patient with newly diagnosed MCL, it is important to establish prognostic disease biology factors such as classical nodal morphology vs blastoid variant vs leukemic variant, TP53 mutation status, and Ki-67 reflective of proliferation.

Investigation of Pembrolizumab De-Escalation After pCR Aims to Challenge SOC in Early-Stage TNBC

June 27th 2023

Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.

MB-106 Generates Responses in BTK Inhibitor–Refractory Waldenström Macroglobulinemia

June 26th 2023

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor.

AZD4573 Elicits Responses in Relapsed/Refractory Peripheral T-cell Lymphoma

June 26th 2023

Single-agent treatment with the CDK9 inhibitor AZD4573 produced clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma.

Cilta-Cel Provides Sustained Efficacy and Safety in Relapsed/Refractory Multiple Myeloma

June 26th 2023

Nikhil C. Munshi, MD, discusses the significance of the FDA approval of cilta-cel in patients with multiple myeloma, shares the long-term findings from the pivotal CARTITUDE-1 trial, and highlights future directions for CAR T-cell therapy in this disease.

Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia

June 26th 2023

The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.

Huntsman Cancer Institute Expands Lifesaving Impact across Utah with Plans for New Comprehensive Cancer Center

June 26th 2023

Huntsman Cancer Institute at the University of Utah, a pioneering innovator dedicated to developing more effective ways to care for and prevent cancer, announced plans today for a new Huntsman Cancer Institute comprehensive cancer center in Utah County.